BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25307308)

  • 1. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014 Oct; ():. PubMed ID: 25307308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.
    Priya B; Ravi S; Kirubakaran S
    Drug Discov Today; 2023 Aug; 28(8):103662. PubMed ID: 37302542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
    Saha J; Wang M; Cucinotta FA
    DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Mercaptoethanol protects against DNA double-strand breaks after kidney ischemia and reperfusion injury through GPX4 upregulation.
    Moon D; Padanilam BJ; Jang HS; Kim J
    Pharmacol Rep; 2022 Oct; 74(5):1041-1053. PubMed ID: 35989399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    Gulliver C; Hoffmann R; Baillie GS
    Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM and ATR as therapeutic targets in cancer.
    Weber AM; Ryan AJ
    Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific Human ATR and ATM Inhibitors Modulate Single Strand DNA Formation in
    da Silva RB; Bertoldo WDR; Naves LL; de Vito FB; Damasceno JD; Tosi LRO; Machado CR; Pedrosa AL
    Front Cell Infect Microbiol; 2021; 11():802613. PubMed ID: 35059327
    [No Abstract]   [Full Text] [Related]  

  • 10. Ku70/80 modulates ATM and ATR signaling pathways in response to DNA double strand breaks.
    Tomimatsu N; Tahimic CG; Otsuki A; Burma S; Fukuhara A; Sato K; Shiota G; Oshimura M; Chen DJ; Kurimasa A
    J Biol Chem; 2007 Apr; 282(14):10138-45. PubMed ID: 17272272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
    Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
    Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
    Shao J; Huang L; Lai W; Zou Y; Zhu Q
    Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA repair mechanisms in cancer.
    Furgason JM; Bahassi el M
    Pharmacol Ther; 2013 Mar; 137(3):298-308. PubMed ID: 23107892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
    Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
    Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
    Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
    Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
    Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
    J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication protein A2 phosphorylation after DNA damage by the coordinated action of ataxia telangiectasia-mutated and DNA-dependent protein kinase.
    Wang H; Guan J; Wang H; Perrault AR; Wang Y; Iliakis G
    Cancer Res; 2001 Dec; 61(23):8554-63. PubMed ID: 11731442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond the Trinity of ATM, ATR, and DNA-PK: Multiple Kinases Shape the DNA Damage Response in Concert With RNA Metabolism.
    Burger K; Ketley RF; Gullerova M
    Front Mol Biosci; 2019; 6():61. PubMed ID: 31428617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.
    Sakasai R; Teraoka H; Takagi M; Tibbetts RS
    J Biol Chem; 2010 May; 285(20):15201-15208. PubMed ID: 20304914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ATR in cancer medicine.
    Sundar R; Brown J; Ingles Russo A; Yap TA
    Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.